Metastatic uveal melanoma continues to have a poor prognosis with distinct pathophysiology from cutaneous melanoma and limited effective treatment options. Targeted therapy with darovasertib towards protein kinase C is well tolerated with signals of early efficacy, warranting further exploration and combination strategies.